BioCentury
ARTICLE | Company News

Management tracks: Vericel, Theravance, Eisai

June 4, 2019 10:41 PM UTC

Cell therapy company Vericel Corp. (NASDAQ:VCEL) disclosed in an SEC filing that Daniel Orlando resigned as COO on May 28 to become CEO of a private biotech company. SVP, Quality and Regulatory Affairs Michael Halpin will succeed Orlando as COO, effective June 15.

Inflammation and immunology company Theravance Biopharma Inc. (NASDAQ:TBPH) hired Andrew Hindman as SVP and CFO. Hindman, formerly CBO of Acorda Therapeutics Inc. (NASDAQ:ACOR), succeeds Renee Gala, who stepped down as SVP and CFO in October. Gala is now CFO of Grail Inc. (Menlo Park, Calif.). ...